At the molecular level, ∼14% of morphologically and immunophenotypically characteristic clear cell carcinomas display a profile of mutations (mutations in TP53 and PPP2R1A; wild-type PTEN, CTNNB1, and ARID1A) typically seen in serous carcinoma 47,48. The gene discussed is TP53; the disease is serous adenocarcinoma.